Potent and selective DYRK inhibitor (IC50 = 0.7 nM for DYRK3, similar potency for DYRK1 and 2). Exhibits ~20-fold selectivity over casein kinase 2 and negligible activity against a panel of 451 kinases screened. Enhances number of CFU-E stimulated by Epo from human marrow. Increases hemoglobin levels in anemic mice. Orally bioavailable.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 401.27. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.49 mL||12.46 mL||24.92 mL|
|5 mM||0.5 mL||2.49 mL||4.98 mL|
|10 mM||0.25 mL||1.25 mL||2.49 mL|
|50 mM||0.05 mL||0.25 mL||0.5 mL|
References are publications that support the biological activity of the product.
Erickson-Miller et al (2007) GSK626616: A DYRK3 inhibitor as a potential new therapy for the treatment of anemia. Blood 110 510
Wippich et al (2013) Dual specificity kinase DYRK3 couples stress granule condensation/dissolution to mTORC1 signaling. Cell 152 791 PMID: 23415227
Rai et al (2018) Kinase-controlled phase transition of membraneless organelles in mitosis. Nature 559 211 PMID: 29973724
If you know of a relevant reference for GSK 626616, please let us know.
View Related Products by Product Action
Keywords: GSK 626616, GSK 626616 supplier, GSK626616, potent, dyrk1, dyrk2, dyrk3, dual, specificity, tyrosine, phosphorylation, regulated, kinases, inhibitors, inhibits, selective, DYRK, 6638, Tocris Bioscience
Citations for GSK 626616
Citations are publications that use Tocris products.
Currently there are no citations for GSK 626616. Do you know of a great paper that uses GSK 626616 from Tocris? Please let us know.
Reviews for GSK 626616
There are currently no reviews for this product. Be the first to review GSK 626616 and earn rewards!
Have you used GSK 626616?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.